Prostate Specific Antigen (PSA) Testing Market is expected to reach a revenue of $2888.96 million by 2023 at a CAGR of 4.14% during the forecast period

Published By: IndustryARC Published On : 18-Sep-2018
According to the new market research report by IndustryARC titled “

Prostate Specific Antigen (PSA) Testing Market: By Type (Free Prostate Specific Antigen Test, Complex Prostate Specific Antigen Test, Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test); By Assays (Radioimmunoassay, Enzyme Immunoassay); By Geography - Forecast (2018-2023)

”, the market is expected to reach a revenue of $2888.96 million by 2023 at a CAGR of 4.14% during the forecast period. Increasing number of reimbursement policies drive the demand for the Prostate Specific Antigen (PSA) Market during the forecast period.

Browse 48 Market Tables, 176 Figures spread through 180 slides and an in-depth TOC on “

Prostate Specific Antigen (PSA) Testing Market

 (2018 - 2023)


Europe dominates the Prostate Specific Antigen (PSA) Testing Market in the forecast period 


Europe has a larger share of the Prostate Specific Antigen (PSA) Market. It is expected to reach $1238.8 Million by 2023 with a CAGR of 3.37% in the coming years. The growing competition among the service providers is propelling the growth of the market in the region. The growth of PSA testing procedures in North America is attributed to the focus on healthcare. US is the most developed country in the world and has well established healthcare facilities. PSA screening is advantageous to men in the region, especially selected patients. 
In Mexico, prostate specific antigen testing has been implemented in many of its clinic and laboratories. More number of men suffer from prostate cancer in this region. Hence, the need for new diagnostic tools and testing methods has spurred the growth of the Prostate Specific Antigen (PSA) Testing Market during the forecast period. 

Selective type of Regulatory Analysis done in the full report:

 
Free Prostate Specific Antigen Test, also known as FPSA is a major PSA blood test. It uses a blood sample of a man to carry out the test. FPSA is described as the amount of PSA in blood that circulates freely. The test only measures the FPSA which is not bounded to the proteins in the blood. It can predict the risk of prostate cancer in men. 
There are some advantages of FPSA since it reduces the risk of infection. The increasing number of free PSA tests in hospitals and clinics has resulted in the reduction in the use of the number of biopsies. This has a positive impact on the growth of the Prostate Specific Antigen (PSA) Testing Market. 
Other types of PSA testing methods include Complex Prostate Specific Antigen and Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction test. Complex Prostate Specific Antigen test is carried out to detect prostatic hyperplasia over the total PSA test. 

To access / purchase the full report browse the link below



Excerpts on market growth factors:


Prostate specific antigen test can detect a fast growing cancer at an early stage. This stops the cancer from spreading. Regular PSA tests can be helpful for men. This factor drives the growth of the market. 
Improvements in the PSA tests by scientists and regulatory agencies can help the doctors to differentiate between slow growing cancers and potentially lethal cancers. Rising cases of Prostate cancer also drive the demand for PSA Testing. 
The mortality rate has reduced to 23.8 from 23.6. This indicates that the PSA test is very effective in determining prostate cancer. 
Screening approaches in the US and Europe have reduce the mortality rate of prostate cancer in a faster way. 

Talk to one of our sales representative about the full report by providing your details in the link below:


Key players of the Prostate Specific Antigen (PSA) Testing Market:


Quest Diagnostics Inc., Neo Genomics Laboratories Inc., Laboratory Corporation of America Holdings, Bio-Reference Laboratories Inc., Abbott Laboratories are analyzed to be the key players of the prostate specific antigen testing market. Quest Diagnostics provides services in sectors such as diagnostic testing, clinical trials testing, Healthcare IT, and wellness & risk management. Neo Genomics Laboratories provides services in diagnostics and pharma segments. Laboratory Corporation of America Holdings has made a partnership with Capital Health for implementing new services.  

Browse Related Reports:


About IndustryARC:


IndustryARC is a research and consulting firm that publishes more than 500 reports annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business.

We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Contact Us:

Mr. Venkateshwar Reddy
Business Development Manager 

Contact Sales: 

1-614-588-8538 (Ext-101)

Connect with us on LinkedIn

 - https://www.linkedin.com/company/industryarc

Request for Sample

News letter

Type your email below and receive our daily news and updates for free